EP2215260A4 - COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE VEHICULATED INTRACELLULAR SIGNAL TRANSDUCTION - Google Patents

COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE VEHICULATED INTRACELLULAR SIGNAL TRANSDUCTION

Info

Publication number
EP2215260A4
EP2215260A4 EP08842968A EP08842968A EP2215260A4 EP 2215260 A4 EP2215260 A4 EP 2215260A4 EP 08842968 A EP08842968 A EP 08842968A EP 08842968 A EP08842968 A EP 08842968A EP 2215260 A4 EP2215260 A4 EP 2215260A4
Authority
EP
European Patent Office
Prior art keywords
vehiculated
compositions
methods
signal transduction
intracellular signal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08842968A
Other languages
German (de)
French (fr)
Other versions
EP2215260A1 (en
Inventor
Richard L Watson
Anthony B Wood
Gregory J Archambeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdiffusion Inc
Original Assignee
Microdiffusion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/en
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/en
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/en
Application filed by Microdiffusion Inc filed Critical Microdiffusion Inc
Publication of EP2215260A1 publication Critical patent/EP2215260A1/en
Publication of EP2215260A4 publication Critical patent/EP2215260A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
EP08842968A 2007-10-25 2008-10-23 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE VEHICULATED INTRACELLULAR SIGNAL TRANSDUCTION Withdrawn EP2215260A4 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US98271907P 2007-10-25 2007-10-25
US98272007P 2007-10-25 2007-10-25
PCT/US2007/082581 WO2008115290A2 (en) 2006-10-25 2007-10-25 Methods of wound care and treatment
PCT/US2007/082578 WO2008052143A2 (en) 2006-10-25 2007-10-25 Mixing device and output fluids of same
PCT/US2007/082580 WO2008052145A2 (en) 2006-10-25 2007-10-25 Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US4834008P 2008-04-28 2008-04-28
US4834708P 2008-04-28 2008-04-28
US4833208P 2008-04-28 2008-04-28
US4840408P 2008-04-28 2008-04-28
PCT/US2008/081021 WO2009055614A1 (en) 2007-10-25 2008-10-23 Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Publications (2)

Publication Number Publication Date
EP2215260A1 EP2215260A1 (en) 2010-08-11
EP2215260A4 true EP2215260A4 (en) 2011-04-20

Family

ID=42261767

Family Applications (3)

Application Number Title Priority Date Filing Date
EP08842968A Withdrawn EP2215260A4 (en) 2007-10-25 2008-10-23 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE VEHICULATED INTRACELLULAR SIGNAL TRANSDUCTION
EP08841701.9A Active EP2214707B1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
EP08841991A Withdrawn EP2224924A4 (en) 2007-10-25 2008-10-24 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP08841701.9A Active EP2214707B1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating inflammation
EP08841991A Withdrawn EP2224924A4 (en) 2007-10-25 2008-10-24 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

Country Status (8)

Country Link
EP (3) EP2215260A4 (en)
JP (6) JP5613565B2 (en)
CN (5) CN101910412B (en)
AU (3) AU2008316794B2 (en)
CA (3) CA2703672A1 (en)
IL (3) IL205317A (en)
MX (3) MX2010004563A (en)
WO (1) WO2009055614A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
CA2667791A1 (en) 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
JP5306214B2 (en) 2006-10-25 2013-10-02 リバルシオ コーポレイション Mixing equipment
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
WO2009055620A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
CA2703672A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
JP5539965B2 (en) * 2008-04-28 2014-07-02 レバレジオ コーポレイション Compositions and methods for treating multiple sclerosis
CA2723215A1 (en) 2008-05-01 2009-11-05 Revalesio Corporation Compositions and methods for treating digestive disorders
CA2741336A1 (en) * 2008-10-22 2010-04-29 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
CA2758738A1 (en) * 2009-04-27 2010-11-04 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
CN104983740A (en) * 2010-05-07 2015-10-21 利发利希奥公司 Compositions and methods for enhancing physiological performance and recovery time
KR20130050952A (en) 2010-06-16 2013-05-16 브루스 챈들러 메이 Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
JP2013533320A (en) 2010-08-12 2013-08-22 レバレジオ コーポレイション Compositions and methods for treating tauopathy
AU2011289176B2 (en) * 2010-08-13 2015-09-24 Revalesio Corporation Compositions and methods for treating cardiovascular disease
CN103561722A (en) * 2011-04-13 2014-02-05 利发利希奥公司 Compositions and methods for inhibiting and/or modulating effector T cells involved in inflammatory neurodegenerative diseases
JP6368459B2 (en) * 2012-06-14 2018-08-01 松本　高明 Method for producing ophthalmic solution
ES2654093T3 (en) 2013-03-13 2018-02-12 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
CA2901413A1 (en) 2013-03-13 2014-10-09 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of vasculitis
RU2672871C2 (en) 2013-03-13 2018-11-20 Инфламматори Респонс Ресёрч, Инк. Use of levocetirizine and montelukast in treatment of traumatic injury
JP2017526728A (en) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Levocetirizine and montelukast in the treatment of inflammation-mediated conditions
CN106943593A (en) * 2017-03-24 2017-07-14 浙江中医药大学 Application of the anti-TSLP antibody in the chronic itch medicine of preventing and treating is prepared
KR20200035235A (en) * 2017-05-23 2020-04-02 바이오바이트 오스트레일리아 피티와이 엘티디 Extracts from Arturospira and uses thereof
EP4153178A4 (en) 2020-05-19 2024-06-05 Irr, Inc. LEVOCETIRIZINE AND MONTELUKAST USED IN THE TREATMENT OF SEPSIS AND ITS SYMPTOMS
CN112305153B (en) * 2020-10-16 2022-09-23 中石化石油工程技术服务有限公司 Automatic analysis detector for bentonite content and detection method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6386751B1 (en) * 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
DE10227818A1 (en) * 2002-06-21 2004-01-08 Pakdaman, Abolghassem, Prof. Dr.med. Gas enrichment modules
WO2004022098A1 (en) * 2002-09-09 2004-03-18 Borsos Ferenc Oxygen-enriched water, treated within a magnetic field and heavy water
US20050047270A1 (en) * 1997-10-24 2005-03-03 Wood Anthony B. System and method for therapeutic application of dissolved oxygen
WO2005113026A2 (en) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Method of treating respiratory disorders and airway inflammation
US20060216360A1 (en) * 2005-03-28 2006-09-28 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (II) antitumour agents
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518483D0 (en) * 1995-09-09 1995-11-08 Thompson Royce Ltd Lighting control systems
DK1100811T3 (en) * 1998-07-28 2007-11-05 Univ California Nucleic acids that encode a G protein-coupled receptor involved in sensory transduction
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
NZ518605A (en) * 1999-10-26 2004-03-26 Bio Hydration Res Lab Inc Micro-cluster liquids and methods of making and using them
JP2003516150A (en) * 1999-12-08 2003-05-13 ジェンセット Full-length human cDNA encoding a cryptic secretory protein
US7255881B2 (en) * 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
AU2001292867A1 (en) * 2000-09-20 2002-04-02 The Cleveland Clinic Foundation Ligands for g protein coupled receptors and methods of using them
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
JP2004529090A (en) * 2001-02-01 2004-09-24 ハイドロン テクノロジーズ，インク． Hyperoxygenated compositions and methods for supplying oxygen to tissue
GB0118383D0 (en) * 2001-07-27 2001-09-19 Pharmagene Lab Ltd Therapeutic methods
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
CN1922156A (en) * 2003-11-10 2007-02-28 默克公司 Substituted triazoles as sodium channel blockers
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
EP2594272B1 (en) * 2005-05-18 2018-07-11 Horizon Orphan LLC Aerosolized fluoroquinolones and uses thereof
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2667791A1 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
EP2083876A4 (en) * 2006-10-25 2012-09-19 Revalesio Corp METHODS OF CARE AND TREATMENT OF WOUNDS
WO2009055620A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
CA2703672A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6386751B1 (en) * 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
US20050047270A1 (en) * 1997-10-24 2005-03-03 Wood Anthony B. System and method for therapeutic application of dissolved oxygen
DE10227818A1 (en) * 2002-06-21 2004-01-08 Pakdaman, Abolghassem, Prof. Dr.med. Gas enrichment modules
WO2004022098A1 (en) * 2002-09-09 2004-03-18 Borsos Ferenc Oxygen-enriched water, treated within a magnetic field and heavy water
WO2005113026A2 (en) * 2004-04-22 2005-12-01 Medical Discoveries, Inc. Method of treating respiratory disorders and airway inflammation
US20060216360A1 (en) * 2005-03-28 2006-09-28 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (II) antitumour agents
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009055614A1 *

Also Published As

Publication number Publication date
AU2008316623A1 (en) 2009-04-30
JP2014169328A (en) 2014-09-18
IL205317A0 (en) 2010-12-30
CN101910412A (en) 2010-12-08
IL205318A (en) 2017-01-31
EP2224924A4 (en) 2011-01-12
MX2010004563A (en) 2010-07-28
CN103933567A (en) 2014-07-23
JP2011500837A (en) 2011-01-06
JP5869763B2 (en) 2016-02-24
EP2214707A4 (en) 2011-04-20
CN101910412B (en) 2013-08-21
MX2010004564A (en) 2010-07-28
CN101909648B (en) 2014-04-16
IL205318A0 (en) 2010-12-30
MX2010004554A (en) 2010-07-28
WO2009055614A1 (en) 2009-04-30
CA2703672A1 (en) 2009-04-30
CA2703754C (en) 2019-04-09
CA2703739A1 (en) 2009-04-30
EP2214707B1 (en) 2017-07-12
IL205319A0 (en) 2010-12-30
AU2008316794B2 (en) 2015-04-23
JP2014193915A (en) 2014-10-09
EP2224924A1 (en) 2010-09-08
CA2703754A1 (en) 2009-04-30
CN101909623A (en) 2010-12-08
CN101909623B (en) 2015-04-01
JP2014205693A (en) 2014-10-30
JP5613565B2 (en) 2014-10-22
AU2008316663A1 (en) 2009-04-30
JP2011500844A (en) 2011-01-06
AU2008316794A1 (en) 2009-04-30
CN101909648A (en) 2010-12-08
IL205317A (en) 2016-03-31
IL205319A (en) 2016-06-30
JP2011500847A (en) 2011-01-06
AU2008316663B2 (en) 2014-12-18
AU2008316623B2 (en) 2015-01-22
EP2214707A1 (en) 2010-08-11
JP5911197B2 (en) 2016-04-27
CN104771758A (en) 2015-07-15
EP2215260A1 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
EP2215260A4 (en) COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE VEHICULATED INTRACELLULAR SIGNAL TRANSDUCTION
WO2008008857A3 (en) Thiolated macromolecules and methods of making and using thereof
EP2215126A4 (en) COMPOSITIONS AND METHODS FOR MODULATING CELLULAR MEMBRANE RECLAIMING
DK1839071T3 (en) Marine Radar apparatus
EP2187965A4 (en) LIGAND-LINK CONJUGATES OF PSMA BINDING AND METHODS OF USING SAME
EP2046391A4 (en) DRUG VECTORS, THEIR SYNTHESIS, AND METHODS FOR THEIR USE
CR10717A (en) COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS
AP2008004633A0 (en) Method for the synthesis of 5-alkoxymethyl furfural ethers and their use
EP2331558A4 (en) PROTECTED MONOMERS AND DEPROTECTION METHODS FOR RNA SYNTHESIS
HUE056772T2 (en) Biaxally oriented microporous membrane
GB201020953D0 (en) Nanopore membrane
EP2046996A4 (en) METHODS FOR DRUG SELECTION
EP1980089A4 (en) Non-intrusive signal quality assessment
NO20045647D0 (en) Acoustic transducers for pipelines
EP2134171A4 (en) COMPOSITIONS AND METHODS FOR BONE FORMATION AND REMODELING
EP2219491A4 (en) CLAMPING STRAPS AND METHODS FOR MAKING, SELLING AND USING THEM
EP2012806A4 (en) METHODS AND COMPOSITIONS FOR MODIFYING CELLULAR FUNCTION
WO2008058127A3 (en) Agonist trkb antibodies and uses thereof
EP1894330A4 (en) SELECTIVE TRANSDUCER FOR COMMUNICATIONS
DK1912476T3 (en) Procedure for training hearing ability
EP2265274A4 (en) ADJUVANTS FOR REDUCING THE TOXICITY OF METHOTREXATE, AND METHODS OF USE
EP2068904A4 (en) METHODS FOR PREPARING DIAZONAMIDES
EP1817423A4 (en) MIXERS FOR CELL CHIMIOLYSIS
EP1873502A4 (en) COMBINED BALANCE FOR WEIGHING MIXTURES
EP2366024A4 (en) COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110321

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/00 20060101ALI20110315BHEP

Ipc: A61K 33/00 20060101ALI20110315BHEP

Ipc: C12Q 1/68 20060101AFI20090520BHEP

17Q First examination report despatched

Effective date: 20120326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170503